ANXA5 and prostate cancer: In human medicine, ANXA5 overexpression has been associated with carcinogenesis (e.g., in cervical carcinoma, breast cancer, fibrosarcoma, osteosarcoma, and prostate cancer), cancer cell invasion, metastasis (e.g., in squamous cell carcinoma and colorectal cancer) and drug resistance (e.g., in gastric cancer, nasopharyngeal carcinoma, glioblastoma multiforme, and large B cell lymphoma) [42,43,44,45,46,47].